Thermo Fisher Scientific priced a $3.8 billion aggregate principal amount of senior notes on February 10, 2026. The notes are scheduled to close on or about February 12 and will pay semi‑annual interest. Net proceeds will be used primarily to fund the cash consideration for the pending acquisition of Clario Holdings, Inc., with any remaining funds earmarked for general corporate purposes such as future acquisitions, debt refinancing, working capital or equity repurchases.
The Clario deal, valued at roughly $8.875 billion to $9.4 billion, is a strategic move to strengthen Thermo Fisher’s clinical research services and data‑analytics capabilities. Clario’s platform integrates endpoint data from devices, sites and patients, enabling faster, data‑driven decision making in drug development. Management expects the acquisition to be immediately accretive to adjusted earnings per share and operating margin, reinforcing Thermo Fisher’s position as a leader in digital clinical solutions.
The senior notes are structured with maturities ranging from 2031 to 2046, allowing the company to spread debt repayment over a long horizon and match the expected cash flows from the Clario integration. The notes were priced under an effective Form S‑3ASR registration statement filed with the SEC on February 24, 2025. Deutsche Bank Securities, RBC Capital Markets, SMBC Nikko Securities America and Wells Fargo Securities served as joint book‑running managers, underscoring the confidence of major financial institutions in Thermo Fisher’s credit profile.
Thermo Fisher’s recent financial performance provides a solid backdrop for the financing. In Q4 2025 the company reported revenue of $12.21 billion, up 7% year‑over‑year, and adjusted EPS of $6.57, beating analyst expectations. For the full year 2025, revenue was $44.56 billion and adjusted EPS was $22.87. Management has guided 2026 revenue to $46.3 billion–$47.2 billion and adjusted EPS to $24.22–$24.80, reflecting confidence in continued growth and margin stability.
CEO Marc Casper described Clario as “an outstanding strategic fit” that will enhance Thermo Fisher’s software and AI capabilities and deepen client relationships. The acquisition follows the $17.4 billion purchase of PPD in 2021 and aligns with a broader industry trend of consolidating data and AI tools to accelerate clinical development. By adding Clario’s endpoint‑data integration platform, Thermo Fisher positions itself to capture a larger share of the growing digital‑clinical services market.
The $3.8 billion senior notes issuance demonstrates Thermo Fisher’s ability to secure substantial debt financing for large‑scale acquisitions while maintaining a healthy debt‑to‑equity ratio. The move is expected to support the company’s strategic growth agenda and reinforce its leadership in the evolving clinical research landscape.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.